Screening for Electrophysiological Abnormalities in Chronic Hepatitis C Infection: Peripheral Neuropathy and Optic Neuropathy

Aslı Köşkdereloğlu1, Pınar Ortan1, Alpay Ari2, Muhteşem Gedizlioğlu1

1Clinic of Neurology, İzmir Bozyaka Training and Research Hospital, İzmir, Turkey
2Clinic of Infectious Diseases, İzmir Bozyaka Training and Research Hospital, İzmir, Turkey

ABSTRACT

Introduction: To investigate the existence of peripheral and optic neuropathies in asymptomatic individuals with hepatitis C infection.

Methods: Thirty consecutive patients who were followed in a hepatitis C outpatient clinic were recruited for electrophysiological evaluation together with 30 age- and gender-compatible healthy controls. All patients had a detailed neurological examination. The information regarding the disease duration and management with interferons were collected. Nerve conduction studies and visual evoked potentials (VEP) were recorded in all subjects. The results of the patient and control groups were statistically compared.

Results: Of the patients with hepatitis C infection, 16 were females and 14 males. The mean age was 57.5 years, and the average disease duration was 6.43 years. The P100 latencies in the patient group were within normal limits, while the amplitudes were meaningfully small by comparison with the controls. There were some abnormalities in the nerve conduction studies of 15 patients. Sensorial neuropathy was detected in two patients, sensorimotor polyneuropathy in four, carpal tunnel syndrome in seven, and carpal tunnel syndrome and sensorimotor polyneuropathy as comorbid states in another two patients. The nerve conduction studies and VEP parameters were entirely normal in the control group.

Conclusion: Hepatitis C-related neurological abnormalities may occur both in the central and peripheral nervous system. Mononeuritis multiplex, sensorial axonal neuropathy, and multiple mononeuropathies are some of the presentations of the peripheral nervous system involvement. The mode of infection is considered to be via vasculitic mechanisms. In addition, optic neuropathy is a known complication of interferon treatment. Autoantibodies, cytokines, chemokines, and cryoglobulins are accused to play roles in the pathogenesis. In this study, we investigated the involvement of the peripheral nervous system and optic nerves in a group of patients with hepatitis C. The results were in favor of peripheral nerve injury of various types and optic neuropathy of the axonal type.

Keywords: Hepatitis C, peripheral neuropathy, carpal tunnel syndrome, optic neuropathy

INTRODUCTION

Hepatitis C virus (HCV) causes a chronic liver infection, which may also present with extrahepatic organ involvement. Neurological complications are diverse and may be observed in a broad spectrum, ranging from peripheral nervous system (PNS) abnormalities to cognitive dysfunction. HCV is the leading cause of mixed cryoglobulinemia, which is frequently associated with PNS involvement (1,2,3). Although a subacute distal symmetrical sensorimotor peripheral neuropathy (PN) is the most frequent presentation in association with mixed cryoglobulinemia, PN may also be observed in the absence of cryoglobulinemia (4,5). While a sensory and axonal neuropathy is the most common form, rarely mononeuritis multiplex due to vasculitis may appear with a fulminant course (6).

Although the pathophysiology of HCV-related PN is controversial, the deposition of HCV-RNA microparticles and cryoglobulins, direct viral invasion, and perivascular mononuclear inflammation are all accused of the development of HCV-related vasculitic lesions (7,8,9,10). As particles of HCV have been detected in the muscle and nerve biopsies of patients with HCV-related PN, immune mechanisms triggered by the virus itself have been proposed (11). The existence of cryoglobulins in the serum may be a clue of an extensive and more severe infection. However, cryoglobulins are not regarded as the sole factor in the course of vasculitis (12).

Several clinical, electrophysiological, and pathological studies dealing with the relationship between chronic HCV infection and PN exist in the relevant literature. HCV-related PN is quite frequent, while central nervous system involvement is comparatively rare. Various ophthalmological diseases, such as keratoconjunctivitis sicca, macular edema, and ischemic optic neuropathy, have also been reported in the course of HCV infection (13). Cappellari et al. (14) reported the central nervous system involvement, co-existing with HCV-related mixed cryoglobulinemia, by means of evoked potential abnormalities. In addition to PNS infection, subclinical optic neuropathy may also be observed during the course of HCV infection, possibly because of low-dose interferon treatment (15,16,17).

This study aimed to investigate the existence of PNS involvement and a possible optic neuropathy in neurologically and ophthalmologically asymptomatic individuals.

Correspondence Address: Aslı Köşkdereloğlu, İzmir Bozyaka Eğitim ve Araştırma Hastanesi, Nöroloji Kliniği, İzmir, Türkiye
E-mail: copura@gmail.com
Accepted: 11.03.2015
METHODS
Thirty consecutive patients who were registered in a chronic hepatitis outpatient clinic were recruited for the study. Individuals with chronic systemic diseases, such as diabetes, malignancy, autoimmune disorders, chronic renal disease, chronic infections other than HCV, or a history of exposure to a toxic substance, hereditary neuropathy, or known ophthalmological disease were excluded. Of the patients with HCV infection, the disease duration and drug treatments were recorded. Thirty healthy, age- and sex-matched individuals were recruited as controls.
All subjects had a complete neurological examination by a neurologist. Nerve conduction studies (NCS) and visual evoked potential (VEP) studies were performed according to a standardized protocol in all cases. The results were statistically compared. In addition, patients with HCV were classified according to their interferon managements, and the electrophysiological findings of the two groups were statistically compared. The study was performed with written consent from all subjects and was approved by the Izmir regional ethical committee number 2.

Electrophysiological Evaluation

Motor and sensory nerve conduction studies
Electrophysiological studies were conducted in the electrophysiology laboratory of the Izmir Bozyaka Education and Research Hospital, Turkey, with a Medelec Synergy device by two of the authors. Nerve conduction studies were standardized throughout the study using the same recording and stimulation electrodes on four motor and three sensory nerves. Motor nerve conduction velocities (NCV), distal latencies (DL), and compound muscle action potentials (CMAP) of the median, ulnar, peroneal, and tibial nerves were evaluated for testing the motor nerves. For the sensory nerves NCV, DL, and the amplitudes of the sensory action potentials (SAP) of the median, ulnar, and sural nerves were recorded.

The stimuli given from the wrist and elbow were recorded from the abductor pollicis brevis muscle using bipolar surface electrodes with a 3-cm distance between the two electrodes with the belly-tendon method for the median nerve. In a similar manner, the stimuli given from the wrist and elbow were recorded from the abductor digiti minimi muscle for the ulnar nerve; while from the ankle and tibial fossa, the stimuli were recorded from the abductor hallucis muscle for the posterior tibial nerve; and from the ankle and capitulum fibula, they were recorded from the extensor digitorum brevis muscle for the peroneal nerve. In the sensory nerve studies, the median and ulnar nerves were stimulated at the wrist, and SAP amplitudes were recorded from the first and fifth digits, respectively, with antidromically ring electrodes. For the sural nerve, SAP was recorded from mid-calf and stimulated behind the lateral malleolus using disk electrodes. The filter arrangements were within the ranges 20–2,000 Hz for sensory and 2–10,000 Hz for motor nerves. Sensory nerve recordings were completed averaging 8–10 readings. Skin temperatures were measured and corrected if not >33°C for the upper and 32°C for the lower extremities. For a definite polyneuropathy diagnosis, abnormalities in more than one nerve were tested, and the existence of more than one pathological finding, such as a decrease in SAP or CMAP amplitudes, slowing of motor or sensory NCVs, or an increase in motor DL were mandated (18).

Visual evoked potentials
Pattern VEP recordings were accomplished in the same laboratory, with the same device, namely the Medelec Synergy device. The active silver recording electrode was placed on the point 2-cm proximal to the pro-
Neurological complications of HCV other than hepatic encephalopathy do not attain much interest in daily practice. Nevertheless, peripheral nerve involvement may end up in severe disability when left undiagnosed and untreated. Furthermore, they may present with a wide range either diffuse or focal (6). Mixed cryoglobulinemia, a frequent companion of HCV infection, is usually thought as the primary underlying cause of PNS involvement (1,2,3). However, the existence of cryoglobulinemia is not a prerequisite for this (4,5). In the series of mixed cryoglobulinemia, the rate of PN is quite variable, ranging from 9% to 77% (19,20). The difference is mostly due to the accepted diagnostic criteria for PN, namely the existence of paresthetic complaints or electrophysiological evidence.

Table 1. The results of the VEP analysis of the patients and control groups

<table>
<thead>
<tr>
<th>Nerve</th>
<th>Hepatitis C (n=30)</th>
<th>Control group (n=30)</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Left p100 latency (ms)</td>
<td>104.84±7.77</td>
<td>107.72±2.93</td>
<td>NS</td>
</tr>
<tr>
<td>Right p100 latency (ms)</td>
<td>104.91±8.78</td>
<td>108.11±3.56</td>
<td>NS</td>
</tr>
<tr>
<td>Left p100 amplitude (μv)</td>
<td>7.67±3.58</td>
<td>10.72±5.86</td>
<td>0.025*</td>
</tr>
<tr>
<td>Right p100 amplitude (μv)</td>
<td>7.74±3.35</td>
<td>10.00±4.43</td>
<td>0.036*</td>
</tr>
</tbody>
</table>

N: number of the participants; NS: not statistically significant (p>0.05). *p value statistically significant (p<0.05).

Table 2. Nerve conduction studies in the patient group and controls

<table>
<thead>
<tr>
<th>Nerve</th>
<th>Control group (n=30)</th>
<th>Patients (n=30)</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Conduction velocity (m/sn)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Median motor</td>
<td>56.36±4.12</td>
<td>52.80±4.38</td>
<td>0.0019*</td>
</tr>
<tr>
<td>Median sensory</td>
<td>50.96±5.76</td>
<td>49.90±11.86</td>
<td>0.01*</td>
</tr>
<tr>
<td>Ulnar motor</td>
<td>57.66±9.35</td>
<td>57.50±5.25</td>
<td>NS</td>
</tr>
<tr>
<td>Ulnar sensory</td>
<td>53.93±5.22</td>
<td>54.03±7.97</td>
<td>NS</td>
</tr>
<tr>
<td>Tibial motor</td>
<td>45.63±4.91</td>
<td>43.13±4.85</td>
<td>NS</td>
</tr>
<tr>
<td>Peroneal motor</td>
<td>47.66±3.85</td>
<td>44.76±9.98</td>
<td>NS</td>
</tr>
<tr>
<td>Sural sensory</td>
<td>49.20±6.81</td>
<td>41.16±22.00</td>
<td>NS</td>
</tr>
<tr>
<td>Distal latency (ms)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Median motor</td>
<td>3.50±0.33</td>
<td>4.00±0.92</td>
<td>0.0068*</td>
</tr>
<tr>
<td>Ulnar motor</td>
<td>2.52±0.23</td>
<td>2.96±0.52</td>
<td>0.0001*</td>
</tr>
<tr>
<td>Tibial motor</td>
<td>4.51±0.86</td>
<td>4.38±1.00</td>
<td>NS</td>
</tr>
<tr>
<td>Peroneal motor</td>
<td>4.45±0.73</td>
<td>4.44±1.28</td>
<td>NS</td>
</tr>
<tr>
<td>Amplitude (mV)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Median motor</td>
<td>9.80±4.10</td>
<td>9.36±4.75</td>
<td>NS</td>
</tr>
<tr>
<td>Median sensory</td>
<td>25.20±9.83</td>
<td>18.63±10.04</td>
<td>0.01*</td>
</tr>
<tr>
<td>Ulnar motor</td>
<td>11.36±8.58</td>
<td>10.60±4.35</td>
<td>NS</td>
</tr>
<tr>
<td>Ulnar sensory</td>
<td>24.86±9.00</td>
<td>21.53±8.60</td>
<td>NS</td>
</tr>
<tr>
<td>Tibial motor</td>
<td>8.71±3.49</td>
<td>6.28±3.20</td>
<td>0.0067*</td>
</tr>
<tr>
<td>Peroneal motor</td>
<td>5.63±1.79</td>
<td>2.91±1.53</td>
<td>&lt;0.0001*</td>
</tr>
<tr>
<td>Sural sensory</td>
<td>11.80±5.39</td>
<td>9.10±7.05</td>
<td>NS</td>
</tr>
</tbody>
</table>

N: number of the participants; NS: not statistically significant (p>0.05). *p value statistically significant (p<0.05).

DISCUSSION

Neurological complications of HCV other than hepatic encephalopathy do not attain much interest in daily practice. Nevertheless, peripheral nerve involvement may end up in severe disability when left undiagnosed and untreated. Furthermore, they may present with a wide range either diffuse or focal (6). Mixed cryoglobulinemia, a frequent companion of HCV infection, is usually thought as the primary underlying cause of PNS involvement (1,2,3). However, the existence of cryoglobulinemia is not a prerequisite for this (4,5). In the series of mixed cryoglobulinemia, the rate of PN is quite variable, ranging from 9% to 77% (19,20). The difference is mostly due to the accepted diagnostic criteria for PN, namely the existence of paresthetic complaints or electrophysiological evidence.

Table 3. The VEP analysis of the patient group according to the interferon medication

<table>
<thead>
<tr>
<th>IFN1 (n=20)</th>
<th>IFN2 (n=10)</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Left p100 latency (ms)</td>
<td>104.05±8.50</td>
<td>106.32±6.36</td>
</tr>
<tr>
<td>Right p100 latency (ms)</td>
<td>102.74±8.55</td>
<td>109.25±7.96</td>
</tr>
<tr>
<td>Left p100 amplitude (μv)</td>
<td>7.35±3.80</td>
<td>8.28±3.26</td>
</tr>
<tr>
<td>Right p100 amplitude (μv)</td>
<td>7.43±3.65</td>
<td>8.36±2.71</td>
</tr>
</tbody>
</table>

NS: not statistically significant (p>0.05). VEP: visual evoked potentials
The results of viral genome studies suggest that the neuropathy results from virus-triggered immune-mediated mechanisms rather than from direct nerve infection or in situ replication (21). HCV-associated PN is typically sensorimotor painful and asymmetric (22). Nerve conduction studies are the most readily available non-invasive method of evaluating PNS. In this study, NCS revealed abnormalities of various types and degree in approximately half of the neurologically asymptomatic patients with hepatitis C. Twenty percent of the patients had PN, 23.3% CTS, and 6.6% PN associated with CTS. In the relevant literature, symmetric sensorimotor PN of mostly the axonal type and mononeuropathy multiplex are reported in association with hepatitis C infection (22). However, in patients lacking cryoglobulin, demyelinating PN dominate (23,24).

In our patient group, PN associated with CTS was of the axonal type; the rest were demyelinating. In the nerve conduction studies of the hepatitis C group, motor DLS of the median and ulnar nerves were longer, and NCVs of the median and tibial motor and the median sensory nerves were slower than in the controls. In some patients, the sural SAP amplitudes could not be obtained. These findings were in favor of a demyelinating type involvement. The decrease of CMAP amplitudes in the peroneal and tibial nerves, in addition to small SAP amplitudes of median nerves, were suggestive of axonal type peripheral nerve involvement.

There was a positive correlation between the duration of the disease and the development of CTS. In one case report, a patient with hepatitis C neuropathy had undergone successful operations for superimposed nerve compressions (25). In a study conducted in the Amazon region, in a group comprising 78 HCV patients, the rate of CTS was 5.5%, while that of multiple mononeuropathies was 14.1% (26). In another group of 19 hepatitis C patients with rheumatismal symptoms, eight subjects had CTS (27).

Alpha-interferon is an antiviral agent and may be protective against autoimmunity. However, on the contrary, in some cases it may induce autoimmunity. Rarely, new onset or worsening PN simultaneously with alpha-interferon treatment has been reported (28,29). As our patients were all asymptomatic, such a state was not considered at all. Although eight HCV-infected patients with PN had a history of interferon treatment, statistical analysis showed no correlation between interferon management and PN. Similarly, Briani et al. (30) reported no link between alpha-interferon treatment and the development and progression of PN.

The second aim of this study was to investigate the presence of subclinical optic neuropathy in neurologically and ophthalmologically asymptomatic HCV-infected subjects. Optic nerve infection due to HCV is quite rare. Cappellari et al. (14) detected abnormalities of VEP in 44% of patients with HCV-related mixt cryoglobulinemia. Besides, interferons have been characterized with various ophthalmologic side effects (15,16,17). While retinopathy is a common side effect, demyelinating optic neuropathy is seldom reported. In a study by Moschos et al. (31), during the long-term follow-up of the subjects receiving low-dose interferon for chronic hepatitis, the P100 latencies were found to be prolonged. In a similar study, 70% of the patients with normal P100 latencies at the pretreatment phase of the study had prolonged P100 latencies after treatment with interferons for a reasonable period (15). In another report, an optic tract neuropathy developed under low-dose interferon treatment was also mentioned (16). However, in our study, we did not observe any prolongation of the P100 latencies, rather we found a clear decrease in the amplitudes of P100 waves. No report of optic neuropathy of the axonal type exists in the literature. In addition, we found no relation between interferon management and P100 wave latencies or amplitudes. A comparison of interferon-treated and non-treated patients for P100 wave properties is given in Table 3.

In conclusion, subclinical neuropathy is a common finding in patients followed for HCV infection. In this study, we also detected PN in approximately half of the neurologically asymptomatic patients with chronic HCV infection. Histopathological and electrophysiological evaluations of HCV-infected subjects are quite limited in the literature. Therefore, more studies with larger groups are needed.

HCV-related PN is usually treated with antiviral agents at first, and, if non-responsive, immunosuppressive agents like rituximab (32,33). However, as the patients in our group were neither symptomatic nor painful, no treatment was planned except for the standard follow-up.

Although the link between mixed cryoglobulinemia and PN is well-known, the lack of cryoglobulin measurements is one limitation of our study.

Optic neuropathy as a manifestation of the central nervous system involvement is very seldom reported. In our patients, we observed an asymptomatic axonal type infection of the optic nerve independent from interferon management. Further studies supporting the association of HCV infection and axonal optic neuropathy are awaited.

Conflict of Interest: No conflict of interest was declared by the authors.

Financial Disclosure: The authors declared that the study has received no financial support.

REFERENCES

4. Lidove O, Cacoub P, Maisonobe T, Servan J, Thibaut V, Pilette JC, Léger JM, Cacoub P. Hepatitis C virus infection with peripheral neuropathy is not always associated with cryoglobulinaemia. Ann Rheum Dis 2001; 60:290-292. [CrossRef]
13. Misiuk-Hojło M1, Michałowska M, Banach I. Ocular manifestations during he-
14. Cappellari A, Origgi L, Spina MF, Yiannopoulou KG, Meola G, Vanoli M, Camp-
mola A, Gregorini F, Scorza R, Bresolin N. Central nervous system involve-
ment in HCV-related mixed cryoglobulinemia. Electromyogr Clin Neurophy-
sio 2006; 46:149-158.
15. Manesis EK, Moschos M, Brouzas D, Kotsiras J, Petrou C, Theodosiadis G,
Hadziyannis S. Neurovisual impairment: a frequent complication of alpha-in-
[CrossRef]
[CrossRef]
17. Retinopathy caused by interferon alpha associated with ribavirin therapy and
the importance of the electro-oculogram: a case report. J Fr Ophthalmol 2004;
27:257-262.
USA: Williams & Wilkins, 1993.
JC. Extrahepatic manifestations associated with hepatitis C virus infection. A
prospective multicenter study of 321 patients. The GERMIVIC. Groupe d'E-
tude et de Recherche en Medicine Interne et Maladies Infectieuses sur le Virus
de l’Hepatite C. Medicine 2000; 79:47-56. [CrossRef]
Rossi B. Peripheral neuropathy in mixed cryoglobulinemia: clinical and elect-
RK, Belec L. Detection of genomic viral RNA in nerve and muscle of patients
with HCV neuropathy. Neurology 2003; 60:808-812. [CrossRef]
22. Kitada M, Suzuki H, Ichihashi J, Inada R, Miyamoto K, Takahashi T, Mitsui Y,
Fujihara K, Kusunoki S. Acute combined central and peripheral demyelination
[CrossRef]
23. Mestre TA, Corneia de Sil J, Pimentel J. Multifocal central and peripheral demyeli-
[CrossRef]
24. Bezerra ML, Harumi JA, Shinosaki JS, Pedroso JL, Henriques de Aquino CC,
de Souza LT, Baiense RF, Bulle de Oliveira AS. Hepatitis C virus: a rare mani-
festation—remitting relapsing central and peripheral demyelination. Neurol India
2011; 59:114-116. [CrossRef]
25. Roissen GD, Rodriguez ED, Dellon AL. Surgical treatment of superimposed
neve compressions in hepatitis C neuropathy. Microsurgery 2007; 27:601-
607. [CrossRef]
in patients with hepatitis C virus infection in the Amazon region. Arq Neurop-
siquiatr 2006; 64:600-602. [CrossRef]
27. Lovy MR, Starkebaum G, Uberoi S. Hepatitis C infection presenting with
rheumatic manifestations: a mimic of rheumatoid arthritis. J Rheumatol 1996;
23:979-983.
28. Meriggioli MN, Rowin J. Chronic inflammatory demyelinating polyneuropat-
[CrossRef]
29. Marzo ME, Tintore M, Fabregues O, Montalban X, Codina A. Chronic inflam-
matory demyelinating polyneuropathy during treatment with interferon-alpha.
J Neurol Neurosurg Psychiatry 1998; 65:604. [CrossRef]
30. Briani C, Chemello L, Zarra G, Ermanni M, Bernardini E, Ruggero S, Toffa-
nin E, Gatta A, Battistin L, Cavalletto L. Peripheral neurotoxicity of pegylated
interferon alpha: a prospective study in patients with HCV. Neurology 2006;
67:781-785. [CrossRef]
G. The effect of low dose-interferon alfa treatment on visual evoked poten-
tials. Doc Ophthalmol 1997; 94:215-221. [CrossRef]
32. Cacoub P, Saadoun D, Limal N, Leger JM, Maisonobe T. Hepatitis C virus infec-
tion and mixed cryoglobulinemia vasculitis: a review of neurological compli-
cations. AIDS 2005; 19(Suppl 3):S28-134. [CrossRef]
33. Sansonno D, DeRe V, Lauletta G, Tucci FA, Boiocchi M, Damacco F. Monoc-
lonal antibody treatment of mixed cryoglobulinemia resistant to interferon